Inventor · disambiguated record
Majken Westergaard
Also filed as: WESTERGAARD MAJKEN
17 granted patents·14 pending applications·800 citations·filing 2003–2018
95Inventor score
Files withSANTARIS PHARMA AS12ROCHE INNOVATION CT COPENHAGEN AS9ENZON PHARMACEUTICALS INC2HANSEN BO2ROSENBOHM CHRISTOPH2
Top patents by PatentIndex Score
31 records- 0198US7589190B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionSANTARIS PHARMA AS·Filed 2005·Granted Sep 15, 2009·129 cites·8 claims
- 0297US9708614B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Jul 18, 2017·28 cites·36 claims
- 0397US9428534B2Antisense designSANTARIS PHARMA AS·Filed 2013·Granted Aug 30, 2016·46 cites·78 claims
- 0497US7687617B2Oligonucleotides with alternating segments of locked and non-locked nucleotidesSANTARIS PHARMA AS·Filed 2003·Granted Mar 30, 2010·207 cites·26 claims
- 0595US7741309B2Oligomeric compounds for the modulation of survivin expressionENZON PHARMACEUTICALS·Filed 2009·Granted Jun 22, 2010·120 cites·12 claims
- 0694US7622453B2Oligomeric compounds for the modulation of Bcl-2SANTARIS PHARMA AS·Filed 2004·Granted Nov 24, 2009·114 cites·57 claims
- 0793US7713738B2Oligomeric compounds for the modulation of survivin expressionENZON PHARMACEUTICALS INC·Filed 2004·Granted May 11, 2010·118 cites·9 claims
- 0892US9994850B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Jun 12, 2018·4 cites·19 claims
- 0989US9045518B2Amino-LNA, thio-LNA and alpha-L-oxy-LNCHRISTENSEN SIGNE M·Filed 2003·Granted Jun 2, 2015·19 cites·19 claims
- 1087US8026355B2Oligomeric compounds for the modulation of survivin expressionSANTARIS PHARMA AS·Filed 2010·Granted Sep 27, 2011·10 cites·9 claims
- 1178US7939507B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted May 10, 2011·2 cites·5 claims
- 1275US9447138B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionSANTARIS PHARMA AS·Filed 2013·Granted Sep 20, 2016·1 cites·4 claims
- 1372US2018237777A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 1471US9951333B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Apr 24, 2018·0 cites·30 claims
- 1571US9890383B2Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2017·Granted Feb 13, 2018·0 cites·30 claims
- 1670US2014128591A1Antisense designSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1770US2018237778A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 1868US2014194614A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 1966US2014128586A1Amino-lna, thio-lna and alpha-l-oxy-lnSANTARIS PHARMA AS·Filed 2013·Application pending·0 cites
- 2066US2016168575A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2165US8410071B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionWESTERGAARD MAJKEN·Filed 2011·Granted Apr 2, 2013·1 cites·9 claims
- 2265US2016168576A1Antisense designROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 2362US8173428B2LNA oligonucleotides and the treatment of cancerROSENBOHM CHRISTOPH·Filed 2008·Granted May 8, 2012·1 cites·2 claims
- 2460US9938527B2Potent LNA oligonucleotides for the inhibition of HIF-1A expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2016·Granted Apr 10, 2018·0 cites·12 claims
- 2550US2006154888A1LNA oligonucleotides and the treatment of cancerSANTARIS PHARMA AS·Filed 2005·Application pending·0 cites
- 2649US2004248840A1Oligomeric compounds for the modulation of ras expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2746US2012088907A1Oligomeric compounds for the modulation of survivin expressionHANSEN BO·Filed 2011·Application pending·0 cites
- 2846US2004241717A1Oligomeric compounds for the modulation of thioredoxin expressionSANTARIS PHARMA AS·Filed 2004·Application pending·0 cites
- 2945US2012322848A1Lna oligonucleotides and the treatment of cancerROSENBOHM CHRISTOPH·Filed 2012·Application pending·0 cites
- 3045US2008188432A1Oligomeric compounds for the modulation ras expressionHANSEN BO·Filed 2006·Application pending·0 cites
- 3137US2009118213A1Rna antagonist compounds for the inhibition of apo-b100 expressionHANSEN HENRIK FRYDENLUND·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Majken Westergaard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →